Attune NxT Grant Program

Thank you to the many researchers who submitted proposals

In the spirit of recognizing scientists like you, the Thermo Fisher Scientific Flow Cytometry team developed the 2015 Attune NxT Flow Cytometry Grant Program and opened a call for proposals. The grant award was a 4-laser Invitrogen™ Attune™ NxT Flow Cytometer offered to one researcher’s institution based on the significance, approach, conceptual framework, innovation, creativity, and feasibility of their abstract. Applicants were challenged to explain how the Attune flow cytometer’s novel acoustic focusing technology would further the goals of his or her research, while also having an impact within the life science research community.

We received many highly-qualified blind submissions, which made the decision-making process very difficult. After much deliberation our panel of seasoned subject-matter experts was able to narrow it down to one winner from North America and one winner from Europe.

  • North America—Dr. Charles Prussak from the University of California, San Diego, won for his submission on immune-cell therapy for the treatment of cancer.
  • Europe—Dr. Bruno Sainz of the Universidad Autónoma de Madrid, won for his submission on the development of a state-of-the art liquid biopsy assay for the detection of circulating cancer stem cells fused to macrophages in human blood samples.

About the North American recipient of the 2015 Attune NxT Flow Cytometry Grant program

photo of Dr Charles Prussak

Charles Prussak, Pharm D, PhD has over 25 years’ experience working in academia and the biotech industry developing cell-based therapeutics. Dr Prussak is currently the Director of the Cell Therapy Translational Laboratory (CTTL), which has been created by the University of California, San Diego (UCSD) to serve as the engine to generate translational cell-based therapeutics that take advantage of breakthroughs discovered in UCSD research laboratories. His long history in developing cell-based therapies began at Viagene, Inc., where he was a founding scientist of a pioneering gene therapy company. As Director of Product Development, Dr Prussak was responsible for the creation of the first ex vivo modified cell products and recombinant retroviruses entered into human clinical trials.

After Chiron, Inc., acquired Viagene, Dr Prussak was named Director of Gene Therapy at UCSD and was responsible for the creation and production of cell and gene therapy products for campus researchers. To expand the scope of this program, UCSD joined with the Boehringer Mannheim Corporation to form Molecular Medicine. As President & CEO of Molecular Medicine, Dr Prussak directed the production of gene and cell therapies that were employed in over 20 phase I-III clinical trials conducted in the US and Europe. Following Molecular Medicine, Dr Prussak co-founded Tragen Therapeutics, which developed gene therapies for the treatment of leukemias and solid tumor cancers. Tragen’s lead product employed gene-modified B cell leukemic cells to activate immune responses that sensitized the target cancer to standard chemotherapeutic agents. These ex vivo clinical studies were precursors to current targeted immunotherapies employing immune modulating agents.

About the European recipient of the 2015 Attune NxT Flow Cytometry Grant program

photo of Dr Bruno Sainz

Prior to his appointment at the Madrid School of Medicine, Bruno Sainz obtained a BS in Biology from American University, Washington, DC, USA as well as PhD in Microbiology and Immunology from Tulane University Health Sciences Center in New Orleans, LA, USA. Dr Sainz’ research interests include cancer, cancer stem cells (CSC), CSC-mediated tumorigenesis and metastasis, pancreatic cancer, fibroinflammatory tumor microenvironment, tumor-associated macrophages, pre-metastatic tumor niche, immune-based anti-cancer therapies, anti-CSC drug screening, small-animal models of cancer and infectious disease (chimeric mice and transgenic mice), viral-mediated cancer, hepatitis B virus (HBV) and hepatitis C virus (HCV).

Attune NxT Flow Cytometer


Our Attune Flow Cytometer employs a revolutionary technology—acoustic-assisted hydrodynamic focusing—to align cells prior to interrogation with a laser for your multicolor flow cytometry analysis. This means that you get accurate data even at sample throughput rates that are 10 times faster than traditional cytometers, all in a benchtop instrument that's easy to own, use, and manage.

Find out more about the Attune NxT Flow Cytometer

  photo of the Attune NxT Flow Cytometer

The Attune NxT Flow Cytometer grant program by the numbers (interactive)